Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.49 |
| ▸ | FAAH | O00519 | 6/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560238 | 1.00 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL2561561 | 1.00 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL12285559 | 1.00 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL18774100 | 1.00 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL30902857 | 0.92 | PTGS1 (0.44) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL18937810 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL22267879 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL20670908 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL16069853 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 | |
| SCHEMBL26149732 | 0.91 | PTGS1 (0.46) | PTGS1PTGS2FAAHMGLLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720127-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| EP-4703389-A1 | ANTI-PTK7 ANTIBODY AND USES THEREOF | MabCare Therapeutics (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260041782-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Shanghai Ruotuo Biosciences (CN) | 2026-02-12 | — | — | US | disclosed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12534541-B2 | Anti-PTK7 antibody and uses thereof | MABCARE THERAPEUTICS (CN) | 2026-01-27 | — | — | US | disclosed |
| US-12496354-B2 | CD142 antibodies, antibody-drug conjugates, preparations and uses thereof | MULTITUDE THERAPEUTICS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4605429-A1 | ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2025-08-27 | — | — | EP | disclosed |
| EP-4606822-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF IN RESISTING TUMORS | MULTITUDE THERAPEUTICS INC. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250242044-A1 | ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SEATTLE GENETICS INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SEATTLE GENETICS INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2558475-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | Spirogen Sàrl (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130616-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130616-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041782-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGRT, FCGR2A, NR3C1 | PTGS1 4413/4885PTGS2 4849/4885FAAH 3087/4885 |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | CCNB2, CCNB3, CCNB1 | PTGS1 3763/4885PTGS2 3153/4885FAAH 1748/4885 |
| US-20250242044-A1 | ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF | CD14, BST2, CD22 | PTGS1 4034/4885PTGS2 1752/4885FAAH 4628/4885 |
| US-12534541-B2 | Anti-PTK7 antibody and uses thereof | LTK, IGSF11, IGLV6-57 | PTGS1 3646/4885PTGS2 4083/4885FAAH 4356/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | PTGS1 633/4885PTGS2 1771/4885FAAH 2006/4885 |
| US-12496354-B2 | CD142 antibodies, antibody-drug conjugates, preparations and uses thereof | CD14, BST2, BSG | PTGS1 3851/4885PTGS2 1608/4885FAAH 4665/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | PTGS1 4819/4885PTGS2 4770/4885FAAH 3882/4885 |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | PTGS1 4460/4885PTGS2 4243/4885FAAH 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.